A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use.
about
Treatment of hemophilia B: focus on recombinant factor IX.Research in haemophilia B--approaching the request for high evidence levels in a rare disease.Evaluation of Nonacog Beta Pegol Long-term Safety in the Immune-deficient Rowett Nude Rat (Crl:NIH-Foxn1rnu).A national French noninterventional study to assess the long-term safety and efficacy of reformulated nonacog alfa.Thrombogenicity evaluation in 221 patients with haemophilia B treated with nonacog alfa.
P2860
A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
A prospective registry of Euro ...... uman factor IX, for usual use.
@en
A prospective registry of Euro ...... uman factor IX, for usual use.
@nl
type
label
A prospective registry of Euro ...... uman factor IX, for usual use.
@en
A prospective registry of Euro ...... uman factor IX, for usual use.
@nl
prefLabel
A prospective registry of Euro ...... uman factor IX, for usual use.
@en
A prospective registry of Euro ...... uman factor IX, for usual use.
@nl
P2093
P2860
P921
P1433
P1476
A prospective registry of Euro ...... human factor IX, for usual use
@en
P2093
A Tagliaferri
E Berntorp
E P Mauser-Bunschoten
R Charnigo
P2860
P304
P356
10.1111/J.1365-2516.2011.02685.X
P577
2011-11-02T00:00:00Z